NCT01569659View on ClinicalTrials.gov

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Lurasidone

80 mg/day for up to 30 weeks

DRUG

Lurasidone

Up to 240 mg/day for up to 30 weeks

Trial Locations (2)

60611

Northwestern University Department of Psychiatry and Behavioral Sciences, Chicago

Northwestern University Psychiatric Clinical Research Program, Chicago

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

Northwestern University

OTHER

NCT01569659 - High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia | Biotech Hunter | Biotech Hunter